{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-009663","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2025-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.256302+00:00","generated_at":"2026-05-18T00:06:05.972143+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PTC Therapeutics receives FDA approval for Sephience (sepiapterin) to treat PKU in patients 1 month and older","bullets":["FDA approved Sephience for hyperphenylalaninemia in adult/pediatric patients ≥1 month with sepiapterin-responsive PKU.","Approval based on Phase 3 APHENITY trial and long-term extension data showing significant efficacy and safety.","Broad labeling includes all disease subtypes; PTC CEO states Sephience could become standard of care.","SEPHIENCE recently received EU marketing authorization; reviews ongoing in Japan, Brazil and other countries.","PTC to host conference call July 28 at 5pm ET to discuss approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-009663","json":"https://secwatch.observer/filing/0001558370-25-009663.json","markdown":"https://secwatch.observer/filing/0001558370-25-009663.md","text":"https://secwatch.observer/filing/0001558370-25-009663.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/0001558370-25-009663-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T00:06:05.972143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}